Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients
Authors:
- Liang ShiLSLiang Shi
- Li-Li WuLWLi-Li Wu
- Jian-Rong YangJYJian-Rong Yang
- Xiao-Fei ChenXCXiao-Fei Chen
- Yi ZhangYZYi Zhang
- Zeng-Qiang ChenZCZeng-Qiang Chen
- Cun-Li LiuCLCun-Li Liu
- Sheng-Ying ChiSCSheng-Ying Chi
- Jia-Ying ZhengJZJia-Ying Zheng
- Hai-Xia HuangHHHai-Xia Huang
- Fu-Jun YuFYFu-Jun Yu
- Xiang-Yang LinXLXiang-Yang Lin
Open Access
- 1 April 2014
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (7) , 2979-2986
Abstract
Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients Alpha-fetoprotein;peroxiredoxin3;hepatocellular carcinoma;biomarker; Background: Recently, peroxiredoxin3 (PRDX3) was identified as a novel molecular marker for the progression of hepatocellular carcinoma (HCC). However, its potential clinical application as a serum marker for the early diagnosis and prognosis of HCC has not been investigated. Methods: PRDX3, alpha-fetaprotein (AFP), and other biochemical parameters were measured in serum samples from 297 Chinese patients, including 96 with HCC, 98 with liver cirrhosis (LC), and 103 healthy controls (HCs). Correlations between serum PRDX3 expression and clinicopathological variables and the relationship between serum PRDX3 expression and prognosis were analyzed. Results: Serum PRDX3 was significantly higher in HCC patients than in the LC and HC groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 85.9% and 75.3%, respectively, at a cutoff of 153.26 ng/mL, and the area under the curve was 0.865. Moreover, serum PRDX3 expression was strongly associated with AFP level, tumor diameter, TNM stage, and portal vein invasion. Kaplan-Meier curve analysis revealed that HCC patients with high serum PRDX3 expression had a shorter median survival time than those with low PRDX3 expression. Moreover, serum PRDX3 expression was an independent risk factor for overall survival. The inverse correlation between serum PRDX3 and patient survival remained significant in patients with early-stage HCC and in those with normal serum AFP levels. Conclusions: Serum PRDX3 can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC.Keywords
This publication has 30 references indexed in Scilit:
- MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular CarcinomaAsian Pacific Journal of Cancer Prevention, 2014
- Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosisCancer Science, 2013
- Peroxiredoxin 3 Is a Key Molecule Regulating Adipocyte Oxidative Stress, Mitochondrial Biogenesis, and Adipokine ExpressionAntioxidants & Redox Signaling, 2012
- Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinomaJournal of Gastroenterology, 2011
- Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approachesHepatology, 2011
- Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4The Prostate, 2010
- Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum‐resistant sublinesProteomics, 2010
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinomaCancer Letters, 2008
- The function of the chloroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulationJournal of Experimental Botany, 2002